Reduced dosing frequency of immune checkpoint inhibitors raises survival concerns in advanced cancer

Dr Gwenaëlle Gravis speaks to ecancer about the interim results of the MOIO trial, an academic non-inferiority study on the use of immune checkpoint inhibitors (ICIs) at a reduced dosing frequency for patients with advanced cancer.

The study revealed a clinically significant imbalance in overall survival, suggesting that administering ICIs at a reduced frequency, every 12 weeks, is not recommended outside of clinical trials.

Dr Gravis highlights the need for further research into patient selection.